Eli Lilly's diabetes drug Mounjaro has dethroned Merck's cancer therapy Keytruda as the world's best-selling medication, generating $8.7 billion in Q1 2026 versus Keytruda's $7.9 billion. Keytruda had held the top spot since Q1 2023, when it displaced AbbVie's autoimmune drug Humira.

U.S. Mounjaro revenue hit $4.2 billion, up 59% year-over-year, while international sales surged to $4.4 billion from just $1.2 billion in Q1 2025. The international jump was driven by Mounjaro's addition to China's National Reimbursement Drug List, opening access to the world's second-largest pharmaceutical market.

Combined with Zepbound, which shares the same active ingredient tirzepatide, Lilly's GLP-1 franchise generated $36.5 billion in 2025 versus Keytruda's $31.6 billion. Lilly raised its full-year 2026 revenue guidance on the back of the dominant Q1 print, despite pricing pressure from the Trump administration and competition from compounded copycat versions during prior shortages.